Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Agilus (dantrolene sodium) is a direct-acting skeletal muscle relaxant that blocks calcium release from the sarcoplasmic reticulum. It is indicated for:
Agilus is a prescription medicine and must be administered by a physician experienced in managing malignant hyperthermia, in an emergency or perioperative care setting.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Agilus (dantrolene sodium) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. Given its use in life-threatening emergencies, hospitals are encouraged to maintain a standing stock through NPP. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription or institutional order and, if applicable, an import permit.
Agilus (dantrolene sodium injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Agilus is not commercially marketed in India.
However, hospitals and patients in India can legally access Agilus through the Named Patient Program (NPP) — an import provision that allows access to medicines approved abroad but not yet marketed in India, under proper regulatory documentation.
Agilus is approved in Europe and the UK for the treatment of malignant hyperthermia crisis, ensuring full transparency throughout the process.
Agilus can be made available to hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.
The same active ingredient is also marketed as Dantrium in other markets; NPP can source either brand depending on availability and hospital preference.
Agilus is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.
Named Patient Program supports hospital access to Agilus for malignant hyperthermia emergency preparedness across major cities in India, coordinating documentation, sourcing, and rapid delivery.
Hospitals in Mumbai can stock Agilus through NPP for anesthesia and critical care emergency readiness.
In Delhi, NPP coordinates with hospitals to facilitate timely access to Agilus for surgical and anesthesia departments.
Bangalore's surgical centers work with NPP to maintain Agilus stock for malignant hyperthermia preparedness.
Hospitals in Chennai can access Agilus through NPP, with coordination between hospital pharmacy and the program's regulatory and logistics team.
Hyderabad's surgical and anesthesia centers support access coordination for Agilus through NPP.
NPP facilitates access to Agilus for hospitals in Kolkata for perioperative emergency stock.
Hospitals in Pune can access Agilus through NPP with prescription-based coordination and delivery support.
NPP supports access to Agilus for hospitals in Ahmedabad.
Hospitals in Kochi and across Kerala can access Agilus through NPP's regulated import pathway.
NPP coordinates access to Agilus for hospitals in Chandigarh and the surrounding region.
Hospitals in Jaipur can access Agilus through NPP for surgical emergency preparedness.
NPP facilitates access to Agilus for hospitals in Lucknow and across Uttar Pradesh.
Hospitals in Bhubaneswar can access Agilus through NPP's coordinated import and delivery process.
NPP supports access to Agilus for hospitals in Guwahati and across the Northeast region.
NPP also supports hospitals in other Indian cities not listed above — contact the team to check availability and timelines for your location.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message